Patricia Pleguezuelos, Marina Sibila, Carla Ramírez, Rosa López-Jiménez, Diego Pérez, Eva Huerta, Anna Maria Llorens, Mónica Pérez, Florencia Correa-Fiz, José Carlos Mancera Gracia, Lucas P Taylor, Jennifer Smith, Meggan Bandrick, Stasia Borowski, Gillian Saunders, Joaquim Segalés, Sergio López-Soria, Maria Fort, Mónica Balasch
This study aimed to evaluate the efficacy of a new trivalent vaccine containing inactivated Porcine Circovirus 1-2a and 1-2b chimeras and a Mycoplasma hyopneumoniae bacterin administered to pigs around 3 weeks of age. This trivalent vaccine has already been proved as efficacious in a split-dose regimen but has not been tested in a single-dose scenario. For this purpose, a total of four studies including two pre-clinical and two clinical studies were performed. Globally, a significant reduction in PCV-2 viraemia and faecal excretion was detected in vaccinated pigs compared to non-vaccinated animals, as well as lower histopathological lymphoid lesion plus PCV-2 immunohistochemistry scorings, and incidence of PCV-2-subclinical infection...
December 9, 2022: Vaccines